30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
M&A activity in Latin America and the Caribbean proved robust in the third quarter, bucking the glob...
Read More >
I think the one place where the retirement plan industry has failed is in communication to plan part...
Read More >
On July 9, 2019, the California Senate Judiciary Committee passed Assembly Bill 25 (AB 25), but only...
Read More >
On December 19, 2019, the Senate passed, as part of the Further Consolidated Appropriations Act 2020...
Read More >
Dallas has become the third city in Texas, following Austin and San Antonio, to pass a city ordinanc...
Read More >
This past summer, Cohen Seglias attorneys Roy Cohen, Ashling Ehrhardt, and Sydney Pierce obtained a ...
Read More >